Corvus Pharmaceuticals Inc (CRVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has a cash flow conversion efficiency ratio of -0.068x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.40 Million) by net assets ($225.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Corvus Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
Corvus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Corvus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Corvus Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
0.039x |
|
Vitec Software Group AB (publ)
ST:VIT-B
|
0.018x |
|
Green Plains Renewable Energy Inc
NASDAQ:GPRE
|
-0.050x |
|
STAAR Surgical Company
NASDAQ:STAA
|
0.054x |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
0.022x |
|
Fengfan Power
SHG:601700
|
0.096x |
|
Zhejiang Windey Co Ltd
SHE:300772
|
0.055x |
|
Highpeak Energy Acquisition Corp
NASDAQ:HPK
|
0.081x |
Annual Cash Flow Conversion Efficiency for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Corvus Pharmaceuticals Inc from 2014 to 2025. View CRVS stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.20 Million | $-32.80 Million | -0.536x | +31.36% |
| 2024-12-31 | $32.57 Million | $-25.42 Million | -0.781x | -26.17% |
| 2023-12-31 | $38.68 Million | $-23.93 Million | -0.619x | -28.48% |
| 2022-12-31 | $56.12 Million | $-27.02 Million | -0.482x | -27.44% |
| 2021-12-31 | $97.16 Million | $-36.72 Million | -0.378x | +21.61% |
| 2020-12-31 | $72.15 Million | $-34.78 Million | -0.482x | +8.15% |
| 2019-12-31 | $71.11 Million | $-37.32 Million | -0.525x | -41.28% |
| 2018-12-31 | $110.34 Million | $-40.99 Million | -0.371x | +31.80% |
| 2017-12-31 | $84.83 Million | $-46.21 Million | -0.545x | -159.68% |
| 2016-12-31 | $132.80 Million | $-27.86 Million | -0.210x | -157.59% |
| 2015-12-31 | $-31.10 Million | $-11.33 Million | 0.364x | -44.70% |
| 2014-12-31 | $-159.00K | $-104.73K | 0.659x | -- |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more